Intravenous voriconazole therapy in a preterm infant

Pharmacotherapy

Volumn 25, Issue 6, 2005, Pages 893-898

  Muldrew, Kendre'a M ^a   Maples, Holly D ^a,b,c   Stowe, Cindy D ^a,b   Jacobs, Richard F ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c NONE   (United States)

Author keywords

Amphotericin B; Antifungal agents; Candida albicans; Cyclodextrin; Developmental renal insufficiency; Infant; Phenobarbital; Voriconazole

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN B LIPID COMPLEX; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; DOBUTAMINE; DOPAMINE; FLUCONAZOLE; FUROSEMIDE; GENTAMICIN; LORAZEPAM; METOCLOPRAMIDE; MORPHINE; PHENOBARBITAL; RANITIDINE; TOBRAMYCIN; VANCOMYCIN; VORICONAZOLE;

ANAMNESIS; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; DEVELOPMENTAL DISORDER; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; FUNGUS CULTURE; GRAM NEGATIVE INFECTION; HUMAN; HYDRONEPHROSIS; KIDNEY CALCIFICATION; KIDNEY DYSFUNCTION; LIVER FUNCTION TEST; NEWBORN; PREMATURITY; SEIZURE; TRACHEITIS; URINARY TRACT INFECTION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFUSIONS, INTRAVENOUS; PYRIMIDINES; TRIAZOLES;

EID: 19444378111     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.6.893     Document Type: Article

References (14)

1. Pfizer Inc. Vfend (voriconazole) package insert. New York, NY; 2004.
2. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
3. Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003;41:78-83.
4. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21: 240-8.
5. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safely of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004;48:2166-72.
6. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53.
7. Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due 10 Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998;27:1437-41.
8. van't Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema J, Meis JF. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998;157:1694-6.
9. Maples HD, Stowe CD, Saccente SL, Jacobs RF. Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection. Pediatr Infect Dis J 2003;11:1022-4.
10. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56(suppl 1):37-44.
11. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol 1976;83:367-78.
12. Perrin JH, Field FP, Hansen DA, Mufson RA, Torosian G. β-cyclodextrin as an aid to peritoneal dialysis: renal toxicity of β-cyclodextrin in the rat. Res Commun Chem Pathol Pharmacol 1978;19:373-6.
13. Frijlink HW, Eissens AC, Hefting NR, Poelstra K, Lerk C, Meijer DK. The effect of parenterally administered cyclodextrins on cholesterol level in the rat. Pharm Res 1991;8:9-16.
14. Uekama K, Shiotani K, Irie T, Ishimaru Y, Pitha J. Protective effects of cyclodextrin sulphates against gentamicin-induced nephrotoxicity in the rat. J Pharm Pharmacol 1993;45:745-7.